Heparin-induced vasodilation in human hand veins

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 232-238

  Tangphao, Oranee ^b   Chalon, Stephan ^c   Moreno Jr , Heitor J ^d   Abiose, Ademola K ^e   Blaschke, Terrence F ^f   Hoffman, Brian B ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c Eli Lilly Benelux   (Belgium)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

BROMPHENIRAMINE; ENOXAPARIN; FAMOTIDINE; HEPARIN; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; PHENYLEPHRINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HAND; HISTAMINE RELEASE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VEIN COMPLIANCE; VEIN DILATATION; VEIN TONE;

ADULT; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; HAND; HEPARIN; HUMANS; MALE; REFERENCE VALUES; VASODILATION; VEINS; VOLUNTARY WORKERS;

EID: 0032825424     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70030-5     Document Type: Article

References (28)

1. 1. Hirsh J, Buchanan M. Comparative effects of heparin and LMW heparin on hemostasis. Thromb Res 1991;(suppl XIV):11-7.
2. 2. Jacques LB. Heparin: a unique misunderstood drug. Trends Pharmacol Sci 1982;3:289-91.
3. 3. Mandal AK, Lyden TW, Saklayen MG. Heparin lowers blood pressure: biological and clinical perspectives. Kidney Int 1995;47:1017-22.
4. 4. Wilson SK, Solez K, Boitnott J, Heptinstall RH. The effects of heparin treatment on hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats. Am J Pathol 1981;102:62-71.
5. 5. Yokokawa K, Mandal AK, Kohno M, Horio T, Murakawa K, Yasunari K, et al. Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats. Am J Physiol 1992;263:R1035-41.
6. 6. Susic D, Mandal AK, Kentera D. Heparin lowers the blood pressure in hypertensive rats. Hypertension 1982; 4:681-5.
7. 7. Sealey JE, Gerten JN, Ledingham JGG, Laragh JH. Inhibition of renin by heparin. J Clin Endocrinol Metab 1967; 27:699-705.
8. 8. Abbott EC, Gornall AG, Sutherland DJ, Laidlaw JC, Stiefel M. The influence of a heparin-like compound on hypertension, electrolytes and aldosterone in man. Can Med Assoc J 1966;94:1155-64.
9. 9. Yokokawa K, Mankus R, Saklayen M. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med 1995;123:35-7.
10. 10. Seltzer JI, Gerson JI. Decrease in arterial pressure following heparin injection prior to cardiopulmonary bypass. Acta Anaesth Scand 1979;23:575-8.
11. 11. Casthely PA, Yoganathan D, Karyanis B, Salem M, Yoganathan T, Komer C, et al. Histamine blockade and cardiovascular changes following heparin administration during cardiac surgery. J Cardiothorac Anesth 1990;4:711-4.
12. 12. Yokokawa K, Kohno M, Mandal AK, Tahara K, Yanagisawa M, Takeda T. Heparin suppresses endothelin-1 peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats. J Am Soc Nephrol 1994;4:1683-9.
13. 13. Minami M, Yokokawa K, Kohno M, Ikeda M, Horio T, Kano H, et al. Promotion of nitric oxide formation by heparin in cultured aortic endothelial cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995;22(suppl 1):S146-7.
14. 14. Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagisawa M, Takeda T. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993;92:2080-5.
15. 15. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 1988;332:411-5.
16. 16. Moncada S, Higgs EA. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
17. 17. Piatti PM, Monti LD, Valsecchi G, Conti M, Nasser R, Guazzini B, et al. Effects of low-dose heparin infusion on arterial endothelin-1 release in humans. Circulation 1996;94:2703-7.
18. 18. Li JM, Hajarizadeh H, La Rosa CA. Heparin and protamine stimulate the production of nitric oxide. J Cardiovasc Surg (Torino) 1996;37:445-52.
19. 19. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981;11:237-43.
20. 20. Pan HYM, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta-adrenergic receptor mediated vascular relaxation with aging in man. J Pharmacol Exp Ther 1987;239:802-7.
21. 21. Greenberg PL, Negrin R, Rodgers GM. Hematologic disorders. In: Melmon KL, Morelli HF, Hoffman BB, Nierenberg DW, editors. Clinical pharmacology: basic principles in therapeutics. New York: McGraw-Hill; 1992. p. 524-99.
22. 22. Fareed J, Hoppensteadt D. Pharmacology of the low-molecular-weight heparins. Semin Thromb Hemost 1996;22 (suppl 2):13-8.
23. 23. Bedarida G, Kim D, Blaschke TF, Hoffman BB. Characterization of an inhibitor of nitric oxide synthase in human hand veins. Horm Metab Res 1994;26:109-12.
24. 2-receptor subtypes. J Allergy Clin Immunol 1994;93:606-14.
25. 25. Tiefenbacher CP, Chilian WM. Basic fibroblast growth factor and heparin influence coronary arteriolar tone by causing endothelium-dependent dilation. Cardiovasc Res 1997;34:411-7.
26. 26. Susic D, Mandal AK, Radujkovic G, Vulovic D, Kentera D. Prostaglandin synthesis inhibitors potentiate the antihypertensive effect of heparin in spontaneously hypertensive rats. J Lab Clin Med 1988;111:63-72.
27. 2-histamine receptor-mediated vasodilation varies with aging in humans. Clin Pharmacol Ther 1995;58: 73-80.
28. 28. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990;42:45-83.